NBQX (2,3-dioxo-6-nitro-7-sulfamoyl-benzo[f]quinoxaline) is an antagonist of the AMPA receptor. NBQX blocks AMPA receptors in micromolar concentrations (~10–20 μM) and also blocks kainate receptors .

NBQX (FG9202) is a highly selective and competitive AMPA receptor antagonist. NBQX has neuroprotective and anticonvulsant activity.

2023年2月26日 · NBQX是一种AMPA 结合位点的有效且有鉴别力的 拮抗剂 。 该化合物具有神经保护特性。 图1.NBQX化学结构. NBQX基础信息. 中文名：AMPA拮抗剂；红藻氨酸拮抗剂； AMPA受体拮抗剂. 英文别名NBQX, AMPA / kainate antagonist. CAS号：118876-58-7

We found that only NBQX had an effect on acute seizure development, resulting in a significantly higher number of mice experiencing seizures, an increase in the number of seizures per mouse, a greater cumulative seizure score per mouse and a significantly higher mortality rate …

NBQX is a compound that shows a 30-fold greater affinity for AMPA binding compared to kainate binding, and is essentially inactive at the glycine site of the NMDA receptor. You might find these chapters and articles relevant to this topic.

NBQX (FG9202) 是一种 AMPA 受体拮抗剂。 CAS号 (CAS NO.) 1. 为了您的安全和健康，请穿实验服并戴一次性手套操作。 2. 粉末溶解前请先短暂离心，以保证产品全在管底。 3. 避光干燥 …

NBQX (FG9202) has a high affinity for AMPA and kainate binding sites with little or no affinity for the glutamate recognition site on the NMDA receptor complex.

NBQX (2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F) quinoxaline) is an analogue of the quinoxalinedione antagonists to the non-NMDA glutamate receptor. NBQX is a potent and selective inhibitor of binding to the quisqualate subtype of the glutamate receptor, with no activity at the NMDA and glycine site 3 .

To determine whether AMPA receptor (AMPAR) antagonist NBQX can prevent early mTOR pathway activation and long-term sequelae following neonatal seizures in rats, including later-life spontaneous recurrent seizures, CA3 mossy fiber sprouting, and autistic-like social deficits.